EPS Holdings, Inc. Stock

4282

JP3130770005

Biotechnology & Medical Research

OTC Markets Traded

Latest news: EPS Holdings, Inc.

09-09	Wisdoms Group International Co., Limited entered into an agreement to acquire 24.8% stake in EPS Creative Health Technology Group Limited from EPS Holdings, Inc. for HKD 82 million.	CI
11/09/25	Shanghai EPS and Beijing Global and Ep-Bio Enter into the CRO Services Framework Agreement	CI
02/10/24	EPS Holdings, Inc. agreed to acquire EPS Medical Consultancy Co., Ltd. from EPS Medical Consultancy Services Limited for approximately ¥180 million.	CI
07/10/22	GNI Group Ltd. forms joint venture with EPS in Japan focusing on medical device business	CI
03/10/22	MedPeer,Inc. completed the acquisition of Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others.	CI
03/10/22	MedPeer,Inc. announced that it has received ¥306.9 million in funding from EPS Holdings, Inc.	CI
09/08/22	MedPeer,Inc. entered into an agreement to acquire Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others for Ã‘5000 million.	CI
09/08/22	MedPeer,Inc. announced that it expects to receive Ã‘306.9 million in funding from EPS Holdings, Inc.	CI
31/03/22	Suzuken Co., Ltd. completed the acquisition of 49% stake in EP-PharmaLine Co., Ltd. from EPS Holdings, Inc.	CI
24/12/21	Suzuken Co., Ltd. agreed to acquire 49% stake in EP-PharmaLine Co., Ltd. from EPS Holdings, Inc.	CI
07/09/21	EPS Holdings, Inc.(TSE:4282) dropped from S&P Global BMI Index	CI
31/08/21	Speed Apparel : EPS Creative Setting Up $2 Million Startup Fund	MT
08/07/21	Y&G Limited completed the acquisition of additional 65.7% stake in EPS Holdings, Inc. from Suzuken Co., Ltd., Medical System Network Co., Ltd. and others for ¥ 53.4 billion.	CI

More news

Press Releases: EPS Holdings, Inc.

21/08/17

EPS : Consolidated Earnings Report for the First Nine Months of Fiscal 2017(451KB)

More press releases

Managers and Directors: EPS Holdings, Inc.

Manager	Title	Age	Since
Fei Liang CEO	Chief Executive Officer	51	-
Daruma Nagaoka PSD	President	-	-
Kenji Sakuma PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Yoshinori Ando BRD	Director/Board Member	69	01/12/2011
Kazuki Sekitani BRD	Director/Board Member	70	01/04/2011
Daruma Nagaoka BRD	Director/Board Member	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EPS HOLDINGS, INC.	-0.11%	-0.06%	-	-	691M
WUXI APPTEC CO., LTD.	+0.65%	-3.36%	+36.98%	+60.50%	64.14B
ARGENX SE	+1.81%	+3.60%	+13.26%	+85.55%	55.53B
LONZA GROUP AG	+1.30%	+2.04%	+13.33%	+105.78%	53.03B
IQVIA HOLDINGS INC.	-0.75%	-0.81%	+26.74%	+55.83%	45.99B
BEONE MEDICINES AG	+0.61%	-1.81%	+19.22%	+101.14%	42.45B
REVOLUTION MEDICINES, INC.	+0.73%	+1.38%	+227.95%	+936.92%	40.45B
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	32.25B
GENMAB A/S	-0.45%	+45.37%	+107.53%	+93.77%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-0.44%	+23.18%	-10.77%	24.23B
Average	+0.19%	+4.08%	+53.26%	+163.81%	43.62B
Weighted average by Cap.	+0.46%	+3.49%	+50.21%	+161.62%

See all sector performances

EPS Holdings, Inc., formerly EPS Corporation, mainly offers medical-related services. Contract Research Organization (CRO) segment provides clinical trials operating and management-related services. Site Management Organization (SMO) segment offers clinical research coordinators (CRCs) to medical institutions. Contract Research Organization (CSO) segment provides drug information and awareness advertisement reception service to medical and pharmaceutical, healthcare industries. Pharmaceutical and Medical Information Technology-related segment is engaged in the development and support service of systems used for clinical trials.

Employees

6,716

Sector

Biotechnology & Medical Research

More about the company